Real-life safety profile of mRNA vaccines for COVID-19: An analysis of VAERS database
2023/03/28 by Greta Santi Laurini, Nicola Montanaro, Massimiliano Broccoli +2 · 15 citations
Medicine · Agricultural and Biological Sciences · Immunology and Microbiology · #SARS-CoV-2 and COVID-19 Research #Animal Virus Infections Studies #Immunotherapy and Immune Responses
paper · doi:10.1016/j.vaccine.2023.03.054
Abstract
INTRODUCTION: Since the first COVID-19 messenger RNA vaccines became available globally for emergency or conditional use, post-marketing surveillance activities have been implemented for the monitoring of any adverse events that might arise in daily clinical practice and were not detected earlier during clinical trials. METHODS: Safety data concerning the BNT162b2 and the mRNA-1273 COVID-19 vaccines were collected from the Vaccine Adverse Event Reporting System (VAERS) for the period from December 2020 to October 15, 2021. In addition to a descriptive analysis of individuals who experienced an adverse event after vaccination, a case-non-case analysis was performed by using the Reporting Odds Ratio with 95 % confidence interval as statistical parameter for detecting differences in reporting rates between the two mRNA vaccines. RESULTS: At the cut-off date, a total of 758,040 reports were submitted to VAERS, of which 439,401 were related to the Pfizer-BioNTech (BNT162b2) vaccine and 318,639 to the Moderna vaccine (mRNA-1273). Most common adverse events following immunization for both mRNA vaccines were headache, fatigue, pyrexia, dizziness, nausea, pain, chills, and pain in extremity. A disproportionality was found for BNT162b2 as compared with mRNA-1273 for some events of special interest, such as myocarditis [ROR 2.00; 95 % confidence interval (CI), 1.93-2.06], Bell's palsy (1.34; 1.29-1.39), and anaphylactic shock (3.23; 2.96-3.53). CONCLUSION: Even if some rare adverse events were identified, our survey of post-marketing surveillance has provided further evidence of the favourable safety profile of mRNA vaccines.
Cited by
- Vaccine conspiracy association with higher COVID-19 vaccination side effects and negative attitude towards booster COVID-19, influenza and monkeypox vaccines: A pilot study in Saudi Universities. [europepmc]
- Myocarditis and pericarditis in individuals exposed to the Ad26.COV2.S, BNT162b2 mRNA, or mRNA-1273 SARS-CoV-2 vaccines. [europepmc]
- Unraveling the association between vaccine attitude, vaccine conspiracies and self-reported side effects following COVID-19 vaccination among nurses and physicians in Jordan. [europepmc]
- Responses to Common Misconceptions Relating to COVID-19 Variant-Adapted mRNA Vaccines. [europepmc]
- Serum Troponin I Assessments in 5- to 30-Year-Olds After BNT162b2 Vaccination. [europepmc]
- Long-term risk of autoimmune diseases after mRNA-based SARS-CoV2 vaccination in a Korean, nationwide, population-based cohort study. [europepmc]
- Unlocking insights: Navigating COVID-19 challenges and Emulating future pandemic Resilience strategies with strengthening natural immunity. [europepmc]
- The WHO Algorithm for Causality Assessment of Adverse Effects Following Immunization with Genetic-Based Anti-COVID-19 Vaccines: Pitfalls and Suggestions for Improvement. [europepmc]
- ARNAX is an ideal adjuvant for COVID-19 vaccines to enhance antigen-specific CD4 + and CD8 + T-cell responses and neutralizing antibody induction. [europepmc]
- Considerations for mRNA Product Development, Regulation and Deployment Across the Lifecycle. [europepmc]
- Sex, Age, and COVID-19 Vaccine Characteristics Associated with Adverse Events After Vaccination and Severity: A Retrospective Analysis. [europepmc]
- Real-world feasibility of co-administration of RSV, COVID-19, and influenza vaccines in older adults: a VAERS-based analysis. [europepmc]
- mRNA vaccine platforms and novel delivery systems: From mechanistic principles to clinical translation. [europepmc]
- The intersection of health inequalities and COVID-19: Evidence from National Health Insurance Big Data in South Korea. [europepmc]
- mRNA Vaccine Against Japanese Encephalitis Virus Genotype IV Protects Against Lethal Infection. [europepmc]
Related